References
1. World Health Organization. Cancer Today [Internet]. Geneva, Switzerland; 2021 [cited 2021 July 2]. Available from: https://gco.iarc.fr/today/.
2. Vink MA, Bogaards JA, van Kemenade FJ, de Melker HE, Meijer CJ, Berkhof J: Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly censored national registry data. Am J Epidemiol 2013, 178(7):1161-1169.
3. McCredie MRE, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al: Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. The Lancet Oncology 2008, 9(5):425-434.
4. Sawaya GF, Smith-McCune K, Kuppermann M: Cervical Cancer Screening: More Choices in 2019. JAMA 2019, 321(20):2018-2019.
5. Cheung LC, Egemen D, Chen X, Katki HA, Demarco M, Wiser AL, et al: 2019 ASCCP Risk-Based Management Consensus Guidelines: Methods for Risk Estimation, Recommended Management, and Validation. J Low Genit Tract Dis 2020, 24(2):90-101.
6. Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC, Jr., et al: Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol 2013, 208(3):184 e181-184 e111.
7. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al: Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006, 119(5):1095-1101.
8. de Sanjosé S, Brotons M, Pavón M: The natural history of human papillomavirus infection. Best practice & research Clinical obstetrics & gynaecology 2018, 47:2-13.
9. Qiao YL, Jeronimo J, Zhao FH, Schweizer J, Chen W, Valdez M, et al: Lower cost strategies for triage of human papillomavirus DNA-positive women. Int J Cancer 2014, 134(12):2891-2901.
10. Arbyn M, Antoine J, Valerianova Z, Mägi M, Stengrevics A, Smailyte G, et al: Trends in cervical cancer incidence and mortality in Bulgaria, Estonia, Latvia, Lithuania and Romania. Tumori 2010, 96(4):517-523.
11. Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-Hirsch PP, Mustafa RA, et al: Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev 2017, 8:CD008587.
12. Liu AH, Walker J, Gage JC, Gold MA, Zuna R, Dunn ST, et al: Diagnosis of Cervical Precancers by Endocervical Curettage at Colposcopy of Women with Abnormal Cervical Cytology. Obstet Gynecol 2017, 130(6):1218-1225.
13. Ozgu E, Yildiz Y, Ozgu BS, Oz M, Danisman N, Gungor T: Efficacy of a real time optoelectronic device (TruScreen) in detecting cervical intraepithelial pathologies: a prospective observational study. J Turk Ger Gynecol Assoc 2015, 16(1):41-44.
14. Singer A, Coppleson M, Canfell K, Skladnev V, Mackellar G, Pisal N, et al: A real time optoelectronic device as an adjunct to the Pap smear for cervical screening: a multicenter evaluation. Int J Gynecol Cancer 2003, 13(6):804-811.
15. Li W, Guo Y, Niu H, Jin S, Wang L: Application of TruScreen in detecting ASCUS patients. Asian Pacific Journal of Tropical Medicine 2011, 4(8):669-671.
16. Long S, Lei W, Feng Y, Lv D, Cai Y, Yang P: The feasibilities of TruScreen for primary cervical cancer screening: a self-controlled study. Arch Gynecol Obstet 2013, 288(1):113-118.
17. Ma Y, Di J, Bi H, Zhao Q, Qin T, Xu W, et al: Comparison of the detection rate of cervical lesion with TruScreen, LBC test and HPV test: A Real-world study based on population screening of cervical cancer in rural areas of China. PLoS One 2020, 15(7):e0233986.
18. Wang Z, Kang Y, Yu F, Zhong FH, Huang K, Zhou X, et al: TruScreen detection of cervical tissues for high-risk human papillomavirus-infected women during the COVID-19 pandemic. Future Oncol 2021, 17(10):1197-1207.
19. Suchonska B, Gajzlerska-Majewska W, Wielgos M: Evaluation of a real-time optoelectronic method in the diagnostics of CIN over four years of observations. PLoS One 2021, 16(2):e0247702.
20. Yang H, Zhang X, Hao Z: The diagnostic accuracy of a real-time optoelectronic device in cervical cancer screening: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 2018, 97(29): e11439.
21. World Health Organization. Timeline: WHO’s COVID-19 response [Internet]. Geneva, Switzerland; 2021 [Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline#! accessed July 3, 2021.
22. Sari Aslani F, Safaei A, Pourjabali M, Momtahan M: Evaluation of Ki67, p16 and CK17 Markers in Differentiating Cervical Intraepithelial Neoplasia and Benign Lesions. Iran J Med Sci 2013, 38(1):15-21.
23. Alshenawy HA: Evaluation of p16, human papillomavirus capsid protein L1 and Ki-67 in cervical intraepithelial lesions: potential utility in diagnosis and prognosis. Pathol Res Pract 2014, 210(12):916-921.
24. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al: Cancer statistics in China, 2015. CA Cancer J Clin 2016, 66(2):115-132.
25. Zhang SK, Jia MM, Zhao DM, Wu ZN, Guo Z, Liu YL, et al: Evaluation of p16/Ki-67 dual staining in the detection of cervical precancer and cancer in China. Cancer Epidemiol 2019, 59:123-128.
26. Silva DC, Gonçalves AK, Cobucci RN, Mendonça RC, Lima PH, Cavalcanti GJ: Immunohistochemical expression of p16, Ki-67 and p53 in cervical lesions - A systematic review. Pathol Res Pract 2017, 213(7):723-729.
Table 1. Overall performance of different screening tests for detecting CIN2+